NCT03969823View on ClinicalTrials.gov

Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

NAActive, not recruitingINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

May 23, 2019

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Locally Advanced or Metastatic NSCLC
Interventions
DRUG

Tagrisso

Osimertinib 80mg once daily until disease progression

Trial Locations (3)

Unknown

Seoul National University Bundang Hospital, Seongnam

Borame Medical Center, Seoul

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

SMG-SNU Boramae Medical Center

OTHER

lead

Seoul National University Hospital

OTHER